Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=84 A Study in Advanced Cancer
Advanced Cancer
Primary: Recommended Phase 2 Dose: Maximum Tolerated Dose — 400 milligrams (mg)
Phase 2 N=51 PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
Adenocarcinoma · Colorectal Cancer · Ovarian Cancer
Primary: Number of Participants With Complete Responses (CRs), Partial Responses (PRs,) Stable Disease and Progressive Disease in the Ovarian Cancer and Breast Cancer Cohorts…
Phase 1 N=11 Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
Neoplasms · Prostate Cancer · Lung Cancer
Primary: Number of Participants With Serious and Non-serious Adverse Events — 6; 4 Participants
N/A N=562 Predictive Analytics and Behavioral Nudges to Improve Palliative Care in Advanced Cancer
Cancer
Primary: Number of Study Participants Who Have Completed a Palliative Care Visit Within 3 Months of Enrollment — 22; 130 participants
Phase 1 N=18 HCW9218 in Select Advanced Solid Tumors
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
N/A N=57 Self-affirmation Intervention for People Newly Diagnosed With Advanced Cancer
Neoplasms
Primary: Mean Changes From Baseline in Self-esteem Scores on the Rosenberg Self-esteem Scale (RSES) to Two-, Six-, and Eight Weeks Post Baseline — 23.4; 23.5; 23.7; 24.2 score on…
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=515 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gastric Adenocarcinoma · Esophageal Cancer · Hepatocellular Carcinoma
Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…
Phase 2 N=58 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
Pancreatic Adenocarcinoma Non-resectable · Pancreatic Adenocarcinoma Metastatic · Colorectal Cancer Metastatic
Primary: Overall Survival - Based on Most Recent Scan — 4.66; 7.7 months
N/A N=73 Adolescents and Young Adults (AYAs) With Advanced Cancer
Adolescent and Young Adult Cancer Patient
Primary: Treatment Acceptability Questionnaire — 6.02 score on a scale
Phase 1 N=39 IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Advanced/Metastatic Solid Malignancies
Primary: Overall Response Rate (Confirmed) — 1; 1 Participants
Phase 2 N=170 A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
Neoplasms · Neoplasm Metastasis · Pancreatic Cancer
Primary: Phase 1b: Recommended Phase 2 Dose — 300 milligrams (mg)
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 1 N=54 A Study for Participants With Advanced Cancer
Advanced Cancer · Metastatic Cancer
Primary: Recommended Dose for Phase 2 Studies — 4.0; 6.0 mg/m²/day
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
N/A N=350 Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Non-small Cell Lung Cancer · Small Cell Lung Cancer · Mesothelioma
Primary: Functional Assessment of Cancer Therapy (Quality of Life Measure) — 81.10; 77.70 units on a scale
Phase 2 N=12 Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
N/A N=37 Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2
Critical Illness · Oncology · Communication
Primary: Change in Prognostic Understanding — 0.58; 0.18 units on a scale
Phase 1 N=25 Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Advanced Cancer
Primary: Treatment-related Adverse Events — 19; 103; 85 Number of Treatment-related Adverse Even
Phase 2 N=216 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Cancer
Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT
Phase 2 N=32 Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers
Small Bowel Cancers · Colorectal Cancers
Primary: Objective Response Rate (ORR) for Triple Therapy — 0; 0 Proportion of participants
Phase 1 N=34 Cancer Vaccine Targeting Brachyury Protein in Tumors
Neoplasms · Malignant Solid Tumors · Colon Neoplasms
Primary: Number of Participants With Brachyury-Specific T-cell Responses — 1; 0; 4; 1 Participants
Phase 2 N=45 Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients
Colorectal Cancers
Primary: Overall Survival — 9.25 months
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 1 N=19 Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor
Advanced Solid Tumor · Lung Cancer · Pancreas Cancer
Primary: Safety and Tolerability Assessment of CNSI-Fe(II) — 0; 0; 1; 0 Participants
Phase 4 N=100 Study of Nivolumab for Advanced Cancers in India
Non-Small Cell Lung Cancer (NSCLC) · Non-Small-Cell Lung Carcinoma · Nonsmall Cell Lung Cancer
Primary: Number of Participants With Treatment-related Adverse Events — 25; 4; 1 Count of participants